# A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma

> **NCT07687914** · PHASE2 · NOT_YET_RECRUITING · sponsor: **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.** · enrollment: 50 (estimated)

## Conditions studied

- HCC - Hepatocellular Carcinoma

## Interventions

- **DRUG:** IMM2510, IMM27M

## Key facts

- **NCT ID:** NCT07687914
- **Lead sponsor:** ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-23
- **Primary completion:** 2027-07-23
- **Final completion:** 2028-07-23
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07687914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07687914, "A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07687914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*